Patents by Inventor Kirk W. Johnson

Kirk W. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110275664
    Abstract: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior. In addition, methods are provided for preventing or inhibiting relapse in human subjects having a history of methamphetamine addiction or dependence by the administration of an effective amount of ibudilast.
    Type: Application
    Filed: March 28, 2011
    Publication date: November 10, 2011
    Inventors: Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20110237512
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Application
    Filed: September 29, 2010
    Publication date: September 29, 2011
    Inventor: Kirk W. Johnson
  • Publication number: 20110117213
    Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.
    Type: Application
    Filed: November 17, 2010
    Publication date: May 19, 2011
    Inventors: Kazuko MATSUDA, Yuichi Iwaki, Kirk W. Johnson
  • Patent number: 7915285
    Abstract: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: March 29, 2011
    Assignees: The Regents of the University of Colorado, Medicinova, Inc.
    Inventors: Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20110039873
    Abstract: The substituted pyrazolo[1,5-a]pyridine compounds in accordance with Formula 1 are strong inhibitors of phosphodiesterase and c-Jun N-terminal kinase activity. Accordingly, Formula 1 compounds are candidate therapeutics for treating disease states such as cancer, neuropathic pain, inflammation as well as cognitive disorders such as Parkinson's Disease.
    Type: Application
    Filed: June 8, 2010
    Publication date: February 17, 2011
    Inventors: Federico C.A. GAETA, Kirk W. JOHNSON, Matthew I. GROSS, Annemarie LEDEBOER
  • Publication number: 20100324082
    Abstract: Enantiomerically pure (S)-2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one, (S)-AV1013, is a candidate therapeutic for treating neuroathic pain, addiction behavior and drug withdrawal symptoms. Also described are methods for preparing and using (S)-AV1013, its pharmaceutically acceptable salts as well as pharmaceutically acceptable formulations of the same.
    Type: Application
    Filed: June 22, 2010
    Publication date: December 23, 2010
    Inventors: Kirk W. Johnson, Matthew I. Gross, Federico C.A. Gaeta
  • Patent number: 7829549
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: November 9, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S. A.
    Inventor: Kirk W. Johnson
  • Patent number: 7767654
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: August 3, 2010
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventor: Kirk W. Johnson
  • Patent number: 7749490
    Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: July 6, 2010
    Assignee: The Regents of the University of Colorado
    Inventors: Jurg M. Sommer, Raymond A. Chavez, Kirk W. Johnson, Linda May Rothblum Watkins
  • Publication number: 20100035920
    Abstract: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.
    Type: Application
    Filed: August 31, 2009
    Publication date: February 11, 2010
    Applicant: Avigen, Inc.
    Inventors: Federico C.A. Gaeta, Matthew Gross, Kirk W. Johnson
  • Publication number: 20100028296
    Abstract: Peptides derived from anti-inflammatory cytokines, such as IL-10, are disclosed for use in treatment of neurodegenerative diseases and neuropathic pain indications, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease and trigeminal neuralgia.
    Type: Application
    Filed: May 1, 2006
    Publication date: February 4, 2010
    Inventors: Raymond A. Chavez, Kirk W. Johnson, Jennifer Shumilla, Laura Sanftner
  • Publication number: 20090318437
    Abstract: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.
    Type: Application
    Filed: June 10, 2009
    Publication date: December 24, 2009
    Inventors: Federico C.A. Gaeta, Matthew Gross, Kirk W. Johnson
  • Patent number: 7622256
    Abstract: Methods of antagonizing MIF activity using ibudilast are described. Also described are methods of screening for MIF antagonists. These agents can be used for treating addictions, including drug and behavioral addictions, as well as for treating neuropathic pain.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: November 24, 2009
    Assignee: Avigen, Inc.
    Inventors: Kirk W. Johnson, Sharmila Vijay, Matthew Gross, Federico C. A. Gaeta
  • Publication number: 20090269325
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Application
    Filed: April 13, 2009
    Publication date: October 29, 2009
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventor: Kirk W. Johnson
  • Patent number: 7585875
    Abstract: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: September 8, 2009
    Assignee: Avigen, Inc.
    Inventors: Federico C. A. Gaeta, Matthew Gross, Kirk W. Johnson
  • Publication number: 20090221629
    Abstract: Methods of antagonizing MIF activity using ibudilast are described. Also described are methods of screening for MIF antagonists. These agents can be used for treating addictions, including drug and behavioral addictions, as well as for treating neuropathic pain.
    Type: Application
    Filed: May 7, 2009
    Publication date: September 3, 2009
    Inventors: Kirk W. Johnson, Sharmila Vijay, Matthew Gross, Federico C.A. Gaeta
  • Publication number: 20090209575
    Abstract: The present invention is directed to the use of ibudilast for treating neuropathic pain.
    Type: Application
    Filed: April 17, 2009
    Publication date: August 20, 2009
    Inventors: Kirk W. Johnson, Lance Sultzbaugh, Jennifer Shumilla
  • Patent number: 7534806
    Abstract: The present invention is directed to the use of ibudilast for treating neuropathic pain.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: May 19, 2009
    Assignee: Avigen, Inc.
    Inventors: Kirk W. Johnson, Lance Sultzbaugh, Jennifer Shumilla
  • Publication number: 20090098185
    Abstract: Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.
    Type: Application
    Filed: December 15, 2008
    Publication date: April 16, 2009
    Applicant: AVIGEN, INC.
    Inventor: Kirk W. Johnson
  • Publication number: 20090035256
    Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.
    Type: Application
    Filed: May 26, 2006
    Publication date: February 5, 2009
    Inventors: Jurg M. Sommer, Raymond A. Chavez, Kirk W. Johnson, Linda May Rothblum Watkins